↓ Cooling
Business
A ‘Transformative’ Narcolepsy Drug Opens New Opportunities in Neuroscience
The pharmaceutical company Takeda has released Phase 3 data for oveporexton, a transformative drug targeting narcolepsy type 1 symptoms.
1 trends tracked about this subject — the full history, oldest to newest below.
The pharmaceutical company Takeda has released Phase 3 data for oveporexton, a transformative drug targeting narcolepsy type 1 symptoms.